Expression of 72 kilodalton type IV collagenase (gelatinase A) in benign and malignant ovarian tumors.
BACKGROUND
72 Kilodalton (kd) type IV collagenase is a matrix metalloproteinase that specifically cleaves type IV collagen molecules. The enzyme has been postulated to have an important role in the invasion and spread of malignant tumors.


METHODS
In situ hybridization was used to study the expression of the 72 kd type IV collagenase mRNA in 24 benign, 2 semimalignant, and 15 malignant ovarian tumors and in 5 metastases of ovarian serous adenocarcinomas. The results were correlated with the expression of the mRNA for the alpha 1(IV) chain of type IV collagen and with the corresponding immunohistochemical distribution of the enzyme.


RESULTS
The results showed that the more malignant an ovarian tumor was, the more clearly mRNA expressions for both 72 kd type IV collagenase and the alpha 1(IV) chain could be detected in tumor cells. The expression of both types of mRNAs was localized within the cells of tumor stroma and occurred mainly in fibroblasts and vascular endothelial cells. Epithelial tumor cells only rarely expressed these mRNAs. Immunohistochemical stainings localized the 72 kd collagenase as well to the stromal cells as to the epithelial cells of both benign and malignant tumors.


CONCLUSIONS
The findings indicate that genes for the 72 kd type IV collagenase and for its substrate are simultaneously active in the same cells of the tumor stroma. The difference in the in situ hybridization and immunohistochemical findings could be explained by a possible variation in the metabolic balance between synthesis and accumulation of the protein in different cell types. It can also be proposed that the activity of the 72 kd type IV collagenase would be mediated through a receptor-like mechanism present on epithelial cells which could bind the 72 kd type IV collagenase synthesized elsewhere. There is also a possibility that the gelatinolytic activity of the mesenchymally synthesized 72 kd type IV collagenase would be consumed to degrade extracellular matrix proteins other than basement membranes.
Autio-Harmainen
H
H
Department of Pathology, University of Oulu, Finland.
Karttunen
T
T
Hurskainen
T
T
Höyhtyä
M
M
Kauppila
A
A
Tryggvason
K
K
D000230:Adenocarcinoma / Q000201:enzymology* / Q000473:pathology; D000911:Antibodies, Monoclonal; D001948:Brenner Tumor / Q000201:enzymology / Q000473:pathology; D003537:Cystadenoma / Q000201:enzymology / Q000473:pathology; D005260:Female; D005350:Fibroma / Q000201:enzymology / Q000473:pathology; D015870:Gene Expression; D006801:Humans; D007150:Immunohistochemistry; D017403:In Situ Hybridization; D020778:Matrix Metalloproteinase 2; D008666:Metalloendopeptidases / Q000032:analysis / Q000096:biosynthesis*; D008970:Molecular Weight; D009362:Neoplasm Metastasis; D010048:Ovarian Cysts / Q000201:enzymology* / Q000473:pathology; D010051:Ovarian Neoplasms / Q000201:enzymology* / Q000473:pathology; D012333:RNA, Messenger / Q000032:analysis / Q000096:biosynthesis*
D000911:Antibodies, Monoclonal; D012333:RNA, Messenger; D008666:Metalloendopeptidases; D020778:Matrix Metalloproteinase 2